查詢結果分析
相關文獻
- Oxaliplatin合併鈣和鎂鹽之實證討論
- 氫氟酸中毒--毒藥物諮詢中心之個案分析
- Tandem Spinal Stenosis: Clinical Diagnosis and Surgical Treatment
- Calcified Chronic Subdural Hematoma: Case Report
- A Patient of Primary Hyperparathyroidism with Full-Blown Bone Changes Simulating Malignancy
- Dissolution and Crystallization of Na-Ca Silicate Glasses in Na2CO3 Solutions
- Myxomycetes of Taiwan (10)--Three New Records of Didymium
- 輕量塗布紙不透明度之改善效應
- 利用蔗漿開發無公害紙漿成形紙餐具
- 脫鈣冷凍乾燥異體移植骨於骨再生方面的效果
頁籤選單縮合
題 名 | Oxaliplatin合併鈣和鎂鹽之實證討論=An Evidence-based Practice of Calcium and Magnesium with Oxaliplatin |
---|---|
作 者 | 林為沁; 林志昇; 呂建宏; | 書刊名 | 藥學雜誌 |
卷 期 | 31:1=122 2015.03[民104.03] |
頁 次 | 頁43-48 |
分類號 | 418.31 |
關鍵詞 | 鈣; 鎂鹽; 大腸直腸癌; Oxaliplatin; Neurotoxicity; Neuropathy; Calcium; Magnesium; |
語 文 | 中文(Chinese) |
中文摘要 | 背景:Oxaliplatin 廣泛用於大腸直腸癌手術後的輔助療法 (adjuvant treatment),而 持續性末梢神經病變此副作用會導致輔助療法中斷,影響大腸直腸癌的治癒情況。在 臨床上,有給與鈣和鎂鹽來減緩此副作用的用法。 目的:確認投與鈣和鎂鹽以預防 oxaliplatin 所引起的神經系統副作用的效果。 方法:2011年以實證文獻探討之方式,於實證文獻資料庫中蒐尋文獻。2014年相 同議題以相同之手法重新審視。 結果:於2011年選出3篇 RCT,另取2篇 clinical trials 的文章以輔助分析。兩篇 clinical trials 皆傾向投與鈣和鎂鹽可有效減少 oxaliplatin 引起的神經毒性且對治療效 果無礙,但整體看來證據稍有不足。在 CONcePT 試驗顯示,施打化療時併用與沒有 併用鈣和鎂鹽在預防神經系統副作用方面沒有統計學上的差異,此結果造成 NCCTG N04C7和 Asia Pac J Clin Oncol. 2010 Dec; 6(4): 270-7研究終止,這結論在近期被推翻。 Asia Pac J Clin Oncol. 2010 Dec; 6(4): 270-7截至研究停止時的結果傾向加入鈣和鎂鹽 對神經毒性效果不佳。而 NCCTG N04C7雖提早中斷,其結果還是支持加入鈣和鎂鹽 能減少 oxaliplatin 所引發之神經毒性。然而2014年一篇名為 N08CB/Alliance 的 phase III RCT 顯示投與鈣和鎂鹽並無法預防 FOLFOX 造成的神經病變。 結論:即使在不同的臨床研究中對於投與鈣和鎂鹽用以預防 FOLFOX 療程造成 的神經病變有不同的結果,本院仍於2011年在 oxaliplatin 為基礎的治療療程中加入靜 脈注射鈣和鎂鹽為預先給藥內容 (premedication),以期降低 oxaliplatin 所引起的週邊 神經病變。 |
英文摘要 | Background: Oxaliplatin is used as the adjuvant therapy for colorectal cancer. It has the potential risk to cause sensory neurotoxicity. Calcium/magnesium infusions have been used to decrease the incidence of oxaliplatin-induced neuropathy. AIM: This study will find out the effect of calcium/magnesium infusions on oxaliplatin toxicity. Method: We searched the literatures from PubMed by using the "Evidence Based Medicine". Two clinical trials and four randomized controlled trials were appraised. Result: Although two clinical trials have indicated that calcium/magnesium infusions seemed to reduce incidence and did not affect the efficacy of treatment. In randomized controlled trials, the CONcePT trial, led to discontinuation of the other two randomized controlled trials, suggested shorter "Time to treatment Failure". More recently, a review from the CONcePT trial found no negative response rate. Despite early termination, the "Asia Pac J Clin Oncol. 2010 Dec; 6(4): 270-7" trial indicated that calcium/magnesium infusions failed to decrease the incidence, but the "NCCTG N04C7" trial supported calcium/magnesium infusions as an effective neuroprotectant. However, calcium/magnesium infusions did not substantially decrease oxaliplatin-induced acute neuropathy in phase III randomized clinical trial (N08CB/Alliance). Conclusion: Although different outcomes were indicated by various clinical trials, we included calcium/magnesium infusions as a pre-medication of oxaliplatin-basis regimens in our hospital. |
本系統中英文摘要資訊取自各篇刊載內容。